Investments, Funding & Disinvestment

The agreement was signed by Total CX Interim Chief Executive Officer Aseel Mattar and Ibn Al Nafees Hospital Chief Executive Officer Rahma Jaberi during a ceremony in Bahrain.

The latest agreement aligns with Teva’s broader “Pivot to Growth” strategy, which focuses on strengthening its innovative medicines and biosimilars businesses through collaborations that expand its global pipeline.

The agreement gives Apollo-managed funds and affiliates a non-controlling interest in a newly created entity that will hold Bayer’s LARC portfolio.

MindRank developed MAP as an AI-native drug discovery engine that combines computational biology, chemistry, laboratory experiments and clinical data into a single research platform.

The investment will fund the construction of a new 500,000-square-foot manufacturing facility, along with extensive upgrades to the company’s existing 700,000-square-foot plant in Austin, Texas.

Arprim Consultants presented a master plan and feasibility study led by Principal Architect Jared Momanyi, which sets out a phased approach to meet rising regional healthcare needs.

The ministry and Samsung is exploring plans to establish a state-of-the-art training facility equipped with advanced technologies that can support the practical training of healthcare professionals.

Evonik will use the funding to upgrade major production assets, including large reactors and other critical processing systems.

The Nottingham site also supports Codis’ commercial spray-drying operations in Haverhill, U.K., where the company is increasing capacity by installing a new GEA Pharma-SD PSD-4 commercial spray dryer, with validation planned for 2027.

Under the agreement, Everest Medicines will receive US$112.5 million upfront from Travere Therapeutics and could earn up to US$1.03 billion more in milestone payments if certain clinical, regulatory, and commercial goals are met across five indications.